Glioblastoma is the most aggressive primary brain tumor in adults and due to the invasive nature cannot be completely removed. The WNT inhibitory factor 1 (WIF1), a secreted inhibitor of WNTs, is systematically downregulated in glioblastoma and acts as strong tumor suppressor. The aim of this study was the dissection of WIF1-associated tumor-suppressing effects mediated by canonical and non-canonical WNT signaling. We found that WIF1 besides inhibiting the canonical WNT pathway selectively downregulates the WNT/calcium pathway associated with significant reduction of p38-MAPK (p38-mitogen-activated protein kinase) phosphorylation. Knockdown of WNT5A, the only WNT ligand overexpressed in glioblastoma, phenocopied this inhibitory effect. WIF1 expression inhibited cell migration in vitro and in an orthotopic brain tumor model, in accordance with the known regulatory function of the WNT/Ca 2+ pathway on migration and invasion. In search of a mediator for this function differential gene expression profiles of WIF1-expressing cells were performed. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), a long noncoding RNA and key positive regulator of invasion, emerged as the top downregulated gene. Indeed, knockdown of MALAT1 reduced migration in glioblastoma cells, without effect on proliferation. Hence, loss of WIF1 enhances the migratory potential of glioblastoma through WNT5A that activates the WNT/Ca 2+ pathway and MALAT1. These data suggest the involvement of canonical and non-canonical WNT pathways in glioblastoma promoting key features associated with this deadly disease, proliferation on one hand and invasion on the other. Successful targeting will require a dual strategy affecting both canonical and non-canonical WNT pathways.
INTRODUCTION
Glioblastoma (GBM) is the most frequent and most malignant primary brain tumor in adults. Despite a multidisciplinary therapeutic approach comprising maximal safe surgical resection, followed by radiotherapy with concomitant and adjuvant temozolomide, the prognosis is extremely dismal, with a median overall survival of 15 months. 1 Because of the infiltrative nature GBM almost invariably recur, 2 hence, therapeutic advances for GBM will require a better understanding of the primary mediators of the invasive behavior with the aim to identify druggable targets.
WNT signaling is involved in diverse processes, from early embryonic patterning to regulation of stem cell self-renewal and differentiation. [3] [4] [5] WNT pathway dysregulation can dramatically alter differentiation and cell fate decisions, 6 thus it is not surprising that abnormalities in WNT signaling are found in a wide range of cancers. The most prominent is colorectal cancer where β-catenindependent signaling, also known as canonical WNT signaling plays a crucial role. Aberrant activation of the pathway is mainly mediated by destructive mutations in adenomatous polyposis coli (APC) (80%), prohibiting destruction of β-catenin, or activating mutations in β-catenin (5%). 7, 8 In contrast, the non-canonical WNT pathways, for which WNT5A is a prominent ligand, has been reported to exert a tumor-suppressive effect on colon cancer. 9 The role of activated WNT pathways in GBM is not clear. The pathway is not targeted by mutations in APC or β-catenin, however, several negative regulators have been shown to be inactivated, mainly by epigenetic silencing and/or deletion, and few mutations. [10] [11] [12] Furthermore, aberrant signaling of both the canonical and the non-canonical signaling pathways seem to contribute to the aggressiveness of GBM. Aberrant β-catenin activation has been associated with maintenance of glioma-initiating cells, 13 while non-canonical WNT signaling with increased invasion.
14, 15 We previously described WNT inhibitory factor 1 (WIF1) gene as a strong tumor suppressor gene in GBM, where it is targeted by deletion and/or promoter methylation. 10 WIF1 is a secreted WNT inhibitor that works by sequestering soluble WNT proteins. It prevents the interaction between WNT morphogens and their specific receptors and it has been shown to bind to virtually all WNT agonists. 16 In contrast to other WNT inhibitors like dickkopf (DKK) family members that can inhibit only the β-catenindependent pathway, WIF1 can block the activation of both canonical and non-canonical WNT signaling pathways. Here, we focused on the analysis of two main non-canonical WNT pathways, namely WNT/c-Jun N-terminal Kinases (JNK) and WNT/Ca 2+ to tie down the relationship between WIF1 expression and WNT signaling alterations.
RESULTS

WIF1 expression inhibits both the β-catenin-and the WNT/Ca
2+ pathways without affecting WNT/JNK signaling To identify the molecular pathways involved in the tumorsuppressive phenotype, we set out to analyze both the canonical and several of the known non-canonical WNT signaling pathways. To this effect, a WIF1-inducible GBM cell line LN-229_indWIF1 (TET-ON system, Clontech Laboratories, Mountain View, CA, USA) was constructed that co-expresses dsRed as marker. The WIF1-mediated tumor-suppressing activity was confirmed in this model after orthotopic injection of the cells into the mouse brain. Mice treated with doxycycline (DOX) had a significantly longer survival (P-value of log-rank test = 0.0062; Supplementary Figure 1) . The analysis of the β-catenin/TCF transcriptional activity using the TOP Flash/FOP Flash luciferase-based reporter, confirmed a modest, WIF1-mediated downregulation of the canonical-WNT pathway. (Figure 1a ). Then we focused on WIF1 function in non-canonical WNT pathways. Expression of WIF1 had no impact on transactivation of the AP1 promoter, although the reporter was sensitive to activation by phorbol-12-myristate-13-acetate (6 h, 200 nM). The AP1 reporter serves as readout for WNT/JNK pathway activation, [17] [18] [19] a non-canonical WNT signaling pathway involved in the regulation of the cytoskeleton and cell adhesion. 20 No effects were observed in the control cell line LN-229_ind_dsRED that upon DOX treatment only induces dsRED ( Supplementary Figures 2A and B) . Next we investigated the non-canonical WNT/Ca 2+ pathway, a signal transduction pathway involved in regulation of cellular migration and invasion. 21 The activation was tested using a (Figure 2e ), while no effect was observed on ERK phosphorylation (Supplementary Figure 4C) . ERK inhibition achieved with the specific MEK1/2 inhibitor U0126, neither affected the [Ca 2+ ] (Figure 2e ), nor p38-MAPK phosphorylation (Supplementary Figure 4D) . Taken together this suggests that there is no direct cross-talk between p-38MAPK and ERK1/2.
WNT5A depletion recapitulates the alterations induced by WIF1 expression WNT5A has been described as a regulator of the non-canonical WNT pathway that controls p38-MAPK activity and [Ca 2+ ]. 22 Despite WNT ligands being expressed in GBM, only WNT5A is overexpressed in GBM relative to non-tumoral brain as determined by analyzing two GBM gene expression datasets. The fold change for WNT5A was 3.1 in our dataset (NCH_EORTC), 23 and 2.5 in the GBM-The Cancer Genome Atlas (TCGA) dataset 24 ( Figure 3a) . This raised the question whether downregulation of WNT5A would phenocopy both, the inhibition of p38-MAPK and the reduction of the [Ca 2+ ] observed with WIF1 re-expression. Downregulation of WNT5A using two specific siRNAs (Supplementary Figures 5A and B) , reduced the phosphorylation levels of both p38-MAPK and ERK (Figures 3b and c ; Supplementary Figure 3B ) and the intracellular [Ca 2+ ] (Figure 3d ), recapitulating the phenotype induced by WIF1 expression.
WIF1 expression reduces tumor cell migration in vitro and in vivo Since the WNT/Ca 2+ signaling is essential for regulation of migration, we tested whether WIF1 expression influenced the invasive potential of GBM cells. WIF1 expression significantly reduced migration in both, the Transwell assay and the woundhealing assay (Figures 4a and b) . Proliferation of LN-229_indWIF1 was analyzed to verify that reduction in migration was not a consequence of differences in cell growth. Indeed, WIF1-mediated inhibition of growth was only detectable after 4 days of culture, thus supporting an inhibitory effect on migration (Figure 4c ). Furthermore, neither migration nor proliferation were affected in the control cell line (LN-229_ind_dsRED) in which DOX exposure induces only dsRED expression (Supplementary Figures 2C and D) . Next, we aimed at investigating the relevance of the biological effect of WIF1 observed in vitro in the GBM-derived sphere-line LN-2669GS, a more relevant GBM model. GBM sphere lines maintained under stem cell conditions retain some tumor stem cell properties and most importantly, the ability to grow invasively when xenografted orthotopically into the brain of mice, hence recapitulating this important original feature of GBM. Ectopic expression of WIF1 in LN-2669GS (LN-2669GS_WIF1) reduced the sphere-forming potential in vitro as compared to the respective ] was measured using the FluoForte fluorescence kit, 48 h after transfection with either the WIF1 expression vector or the respective empty vector.
empty vector control (LN-2669GS_IRES; Figure 5a ). Next, the sphere lines were injected orthotopically into the brain of nude mice to evaluate tumorigenicity and invasiveness modulated by WIF1. Mice were killed at the appearance of the first neurological symptoms, such as ataxia and lethargy, or body weight loss, clear signs of tumor growth. The brains were collected, formalin fixed and cut in coronal slices. The Kaplan-Meier curves confirmed the tumor-suppressing function of WIF1 expression in the GBM sphere-line LN-2669GS (log-rank test, P = 0.0046 ( Figure 5b ). The sections taken in the plane of the injection were immunostained for the human-specific antibody anti-nucleolin to identify the human tumor cells. Migration was measured by comparing the number of human tumor cells on the injected versus the contralateral side, in the plane of the injection (Figure 5c ). At the time of killing the mice, which means they were moribund due to the tumor burden, the WIF1-transduced cells (LN-2669GS_WIF1) had migrated less to the contralateral side, reflected in a statistically smaller ratio than the control cells (LN-2669GS_IRES; Figures 5d and e). Hence, suggesting a WIF1-dependent reduced migratory capacity in vivo.
WIF1 regulates the expression of MALAT1, a key positive regulator of migration In order to identify new genes regulated by WIF expression, differential gene expression profiles were obtained for LN229_ind-WIF1 48 h after induction. The time point for the analysis was motivated by the kinetics of WIF1 induction and secretion of WIF1 into the medium. At 48 h the WIF1 concentration in the medium reached a plateau (Figure 6a ). Figure 6b shows the heat map of the most variable transcripts presented as logarithmic fold change compared to the non-induced samples (duplicates). We selected the probes with a log-fold change of 4|1|. Several interesting candidate transcripts emerged, which were then tested in additional experiments by qRT-PCR in LN-229_indWIF1 (Figure 6c) , and in the GBM cell line LN-319 and the sphere-line LN-2669GS transduced with WIF1 ( Supplementary Figures 6A-C) . Across the three lines the most consistent WIF1-dependent change was downregulation of the metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), which was subsequently chosen for further investigations. MALAT1 is a nuclear long non-coding RNA, whose expression has been associated with a migratory phenotype in several cancer types, [25] [26] [27] [28] however, nothing has been reported from GBM. MALAT1 was found overexpressed in GBM as compared to non-tumoral brain (fold change = 1.4, P = 0.0062) in NCH_EORTC dataset. 23 Next, we wanted to elucidate the mechanism for WIF1-mediated downregulation of MALAT1. Both WNT5A depletion ( Figure 6d ) and p38-MAPK inhibition (Figure 6e ) lead to a drastic reduction in MALAT1 transcription. Since WNT5A depletion, in contrast to WIF1 induction, does not affect the canonical WNT pathway, as measured by AXIN2 expression, we conclude that MALAT1 expression is dependent on activation of the non-canonical WNT pathway.
MALAT1 downregulation inhibits invasion without affecting growth MALAT1 was depleted by two siRNAs to test the involvement of MALAT1 in migration of LN-229. The efficacy of the RNAi procedure was assessed by qRT-PCR, measuring expression of MALAT1 at two different time points, 48 and 72 h. To provide functional evidence for downregulation of MALAT1 the expression of two known target genes of MALAT1 were determined, collagen triple helix repeat containing 1 (CTHRC1) and solute carrier family 26 (anion exchanger), member 2 (SLC26a2). 26 Both MALAT1 and the respective target genes displayed significant downregulation (Figure 7a ). The migratory potential of LN-229 depleted of MALAT1 was tested using both the wound-healing assay and the Transwell assay. The wound-healing assay was performed starting 48 h after the siRNA transfection. Downregulation of MALAT1 was sufficient to significantly reduce the area of the scratch covered ( Figures  7b and c) . Similarly, the Transwell assay confirmed a reduction in migration of siMALAT1-transfected cells (Figures 7d and e) . In the wound-healing assay cells were induced with DOX for 24 h, the scratch was made and allowed to heal for 24 and 48 h, respectively, and the uncovered area was quantified (b). A growth curve was performed over 6 days (c) to exclude WIF1-mediated reduction in growth as potential confounding factor. DOX was added at T zero (24 h after seeding).
MALAT1, thus the results obtained were indeed related to a deficit in migration rather than a difference in growth rate (Figure 7f ). The inhibitory effect of MALAT1 on migration was recapitulated in two additional GBM cell lines (LN-18 and LN-428; Supplementary Figure 7 ).
DISCUSSION
Little is known about the role of the WNT pathways in the malignant behavior of human GBM. We previously provided evidence for the tumor-suppressing function of WIF1 in GBM. 10 Here, we addressed the question of WIF1-mediated mechanisms implicated in both the canonical and non-canonical WNT pathways. WIF1 expression inhibited the canonical as well as the WNT/Ca 2+ signaling pathway in GBM cells. WIF1-mediated decrease in intracellular [Ca 2+ ] was found to be associated with a significant inhibition of p38-MAPK phosphorylation, in line with findings in mouse F9 teratocarcinoma cells. 22 However, no effects were detected either on AP1-based reporter activity or phosphorylation of JNK and c-Jun, although JNK-AP1 signaling has been suggested to contribute to the malignant phenotype in GBM. 14, 29 WNT5A depletion was sufficient to recapitulate the effect observed for WIF1 expression, with downregulation of phospho-p38-MAPK and reduction of the intracellular [Ca 2+ ]. Hence, we are providing the first evidence, for an important role of WNT5A/p38-MAPK/Ca 2+ -mediated non-canonical WNT signaling in GBM. Both WNT5A expression and p38-MAPK activation can have opposite effects depending on the cellular context. WNT5A-dependent noncanonical signaling has been described to be tumor suppressive in several types of cancer such as ovarian and colorectal cancer. [30] [31] [32] [33] However, in GBM, WNT5A has been associated with tumor aggressiveness, as its expression has been reported to be essential for the maintenance of the invasive phenotype. 14, 15, 34 Moreover, it has been reported that stable depletion of WNT5A in a GBM cell line induced senescence, 35 which is in line with our previous report showing increased senescence in GBM cell lines ectopically expressing WIF1. 10 The importance of WNT5A in GBM is also supported by the fact that it is the only WNT ligand that is overexpressed as compared to non-tumoral brain.
Similar considerations are also valid for p38-MAPK activation. Although p38-MAPK is involved in the regulation of a plethora of responses, including pro-apoptotic pathways, 36 the final effect is cell-type specific and, in GBM, there is evidence that p38-MAPK activation correlates with malignancy and with the invasive potential. [37] [38] [39] Both the WNT/Ca 2+ pathway and activation of p38-MAPK are involved in the regulation of cell migration in normal development as well as in cancer progression. 40, 41 Here, we provided evidence that in addition to loss of tumorigenicity; 10 WIF1-expressing cells reduce migration both in vitro and in vivo. Moreover, we discovered that the most downregulated gene upon WIF1 induction was MALAT1, a non-coding RNA known to be a strong positive regulator of invasion. Physiologically, MALAT1 localizes to nuclear speckles and regulates alternative splicing by modulating the distribution and levels of splicing factors. 27, 42 MALAT1 has been associated with cell migration and invasive properties of cancer. 26, 28 In GBM, MALAT1
has not yet been investigated. Here, we have clearly shown that MALAT1 expression is regulated by WIF1 expression via the WNT5A/p38-MAPK/Ca 2+ -non-canonical WNT signaling axis. Moreover, MALAT1 expression proved to be extremely important for the maintenance of the migratory potential of GBM cell lines.
Virtually, all GBMs recur which is attributed to the extremely high capability of GBM cells to migrate and to invade the surrounding normal brain structures, precluding complete surgical resection, and effective targeting by irradiation. 43 A better understanding of the key regulatory pathways contributing to the migratory potential of GBM is required for development of WIF1 re-expression in glioblastoma inhibits migration I Vassallo et al successful therapeutic strategies. MALAT1 per se, would probably not be a good candidate because of its high basal level of expression in normal brain. Furthermore, MALAT1 is involved in regulation of numerous genes. Hence, identification of the most important effectors of MALAT1 related to invasiveness would be the next logical step. Taken together, our results clearly show that the final tumorsuppressive phenotype induced by WIF1 is a combination of the inhibition of both canonical and non-canonical WNT pathway(s) as depicted in the model from Figure 8 . We hypothesize that inhibition of the canonical pathway mediates decreased growth, while inhibition of the non-canonical WNT pathway leads to decreased migration. We suggest that inhibition of the noncanonical WNT pathway by WIF1 is mediated by sequestration of WNT5A that results in decrease of p38-MAPK phosphorylation, drop of intracellular [Ca 2+ ] and reduction of MALAT1 expression, resulting in attenuated migration. These findings should be taken into account when developing WNT inhibitors for therapy, as the canonical WNT pathway should not be targeted alone, but rather in combination with inhibition of non-canonical WNT pathway(s) in order to both inhibit tumor growth and migratory properties.
MATERIALS AND METHODS
Cell lines
The adherent GBM cell lines LN-229, LN-319, LN-18 and LN-428, have been established in our laboratory as well as the sphere-line LN-2669GS. 44, 45 The lines were authenticated by DNA fingerprinting. 46 The adherent cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM, Life Technologies, Carlsbad, CA, USA), supplemented with 5% fetal calf serum (FCS) (HyClone, Thermo Fisher, Waltham, MA, USA) and 100 units/ml penicillin and streptomycin (Life Technologies). The sphere-line LN-2669GS was cultured under stem cell conditions using DMEM/F12 medium containing B27 supplement and 20 ng/ml of both epidermal growth factor and fibroblast growth factor 2. LN-229_indWIF1 and LN-229_ind_dsRED were treated with DOX (Clontech, Mountain View, CA, USA) at 1 μg/ml. The following small-molecule inhibitors were used: SB203580 (Calbiochem, La Jolla, CA, USA) and SB239063 (Sigma-Aldrich, St Louis, MO, USA, cat # S0569) specific for p38-MAPK, and the MEK1/2 inhibitor U0126 (Cell Signaling, # 9903, Danvers, MA, USA) for the inhibition of ERK1/2.
Gene expression datasets
Gene expression profiles from the NCH_EORTC GBM cohort was previously described by Murat et al. 23 (HG133 Plus 2.0, Affymetrix, Santa Clara, CA, USA; GBM = 70 and non-tumoral brain = 4, excluding 10 recurrent GBMs) and is deposited in the Gene Expression Omnibus (GEO) database at http:// www.ncbi.nlm.nih.gov/geo/ (accession number GSE7696). The molecular profiles of GBM from TCGA project were downloaded (level 3 data, Agilent (Santa Clara, CA, USA) 244K Custom Gene Expression G4502A-07, GBM = 573 and non-tumoral brain = 10; http://tcga-data.nci.nih.gov/tcga/ tcgaHome2.jsp. 24, 47 Plasmids and small interfering RNAs
The WNT-β-catenin activity luciferase reporter vectors TOP_FLASH and FOP_FLASH and the fusion construct expressing LEF1-β-catenin were generous gifts of Professor Tatiana Petrova. 48 The reporter for AP1 signaling, pGL3-5xTRE-TATA was used to measure the AP1 signaling pathway. The pRL-CMV Renilla luciferase (Promega AG, Fitchburg, WI, USA) plasmid was used to normalize for transfection efficiency. The two WIF1 expression vectors (pcDNA3.1_WIF1 and pIRES2_EGFP_WIF1) were described in Lambiv et al. 10 The list of siRNAs is available in Supplementary Table 1 .
Cell transfection and generation of stable cell lines
Transfections were performed using the NEON electroporator (Life Technologies). For adherent cell lines the parameters were set at 1400 V, 20 ms pulse width, 1 pulse, while for sphere cell lines the voltage was increased to 1700 V. The ratio of DNA/cells was usually 20 μg of DNA/ 4 × 10 6 cells, while the final concentration of transfected siRNA was 25 nM for siWNT5A_#1 and #2, and 15 nM for siMALAT1_#1 and 25 nM for siMALAT1_#2.
For stable transfections, cells were transfected with the expression vector followed by selection with G418 (G418, Geneticin, Life Technologies). Resistant clones were selected and maintained in 400-800 μg/ml of G418. The inducible cell line LN229_indWIF1 was constructed transfecting the following three vectors: the reverse tetracycline transactivator (rtTA), plasmid pUHG 17.1 49 and plasmid pJ6Ω, 50 containing the puromycin-resistance gene (puromycin dihydrochloride, Calbiochem No. 540222, (1 μg/ml)), and either the pTRE-Tight-BI-DsRed-Express vector (Clontech Catalog No. 631065) into which the WIF1 cDNA was cloned, or the respective empty vector for the control cell line (LN229_ind_ dsRED). The vector contains an inducible bidirectional promoter that beside the gene of interest expresses the red fluorescent protein (dsRED_Express).
Luciferase-based assays
Lusiferase experiments were performed using the DUAL Luciferase system (Promega) as suggested by the manufacturer. Luminescence was measured 2 days after transfection with the respective plasmid and analyzed using a Synergy H1 hybrid multi-mode microplate reader.
Intracellular calcium measurement
Intracellular [Ca 2+ ] was determined using the Fluo-Forte calcium assay kit (Enzo Life Sciences, New York, NY, USA) as suggested by the manufacturer 48 h after transfection. Fluorescence was measured using the Synergy H1 hybrid multi-mode microplate reader (excitation 485 and emission 520 nm).
Proliferation assay
Growth curves were established as described previously, 10 briefly 2 × 10 4 cells were seeded in 12-well plates. At every time point, cells were washed with phosphate-buffered saline, and stained with 500 μl of crystal violet solution. Plates were left to dry, and 500 μl of 1% sodium dodecyl sulfate (SDS) in distilled water was added per well. Absorbance was then measured at 595 nm. Growth in soft agar was determined in six-well plates containing 2 ml of 1% agar in complete medium as the bottom layer, and 1 ml of 0.4% agar in complete medium as the top layer; 2 × 10 3 cells were seeded in triplicate. After 3 weeks the number of colonies was determined with an inverted phase-contrast microscope. Clusters of 50 cells were scored as colonies. For the sphere formation assay using limiting dilution the cells were dissociated into single-cell suspensions, and then plated into 96-well plates with various seeding densities (from 250 to 750 cells per well). Two to 3 weeks later each well was examined for the formation of spheres. WIF1 re-expression in glioblastoma inhibits migration I Vassallo et al
Cell migration assays
Transwells (Corning, Tewksbury, MA, USA, 8.0-μm pores) were used to measure migration; 1 × 10 4 cells were suspended in 100 μl of DMEM containing 0.5% FCS and transferred to the upper chamber and 600 μl of 5% FCS medium were applied to the lower chamber. After 16-18 h, the cells on the upper side of the filters were wiped off and the cells that migrated to the lower side were stained with crystal violet. To perform the scratch assay, the cells were plated onto 35-mm-diameter dishes and the monolayer of cells was manually scratched with a plastic tip. After being washed with phosphate-buffered saline, pictures were taken to set the time (T) zero. Pictures were taken at the identical spot at 24 and 48 h. The area of the scratch not yet covered by cells was quantified using ImageJ software, 51 and the data are shown as percentage of covered scratch (T zero = 0%). For the experiment performed with the LN-229_indWIF1, the cells were seeded 24 h before induction with DOX, and the scratch was performed 24 h after DOX treatment. For the Transwell (Corning) assay cells were seeded in the upper chamber 48 h after induction.
Intracranial nude mouse tumorigenicity assay
The protocol was authorized by the local veterinary authorities (VD1181.3-6). Six-week-old Swiss nu/nu mice were stereotactically injected with 1 × 10 5 cells, resuspended in 5 μl (coordinates from the bregma: 0.5 mm anterior, 2 mm lateral and 3 mm depth, stereotactic frame, Stoelting, Wood Dale, IL, USA). Mice were killed at first appearance of neurological symptoms (lethargy, ataxia and seizures) or body weight loss. To test intracranial tumorigenicity of LN-229_indWIF1 mice were fed with DOXsupplemented food (625 μg/kg, Harlan (Indianapolis, IN, USA) TD.01306 Rodent Diet, changed every 2-3 days), the controls received standard food. 52 For survival analyses, 10 mice were used per group for the LN-2669GS while 6 mice per group for the LN-229_indWIF1.
Protein analysis
Proteins were extracted from dry pellets of frozen cells (−80°C) as described previously. 10 Briefly, the pellets were dissolved in RIPA buffer, supplemented with protease inhibitor (cOmplete Mini, Roche, Basel, Switzerland) and phosphatase inhibitor (PhosSTOP, Roche). The lysate was centrifuged at 14 000 g for 10 min at 4°C. The supernatant was collected as whole cell lysate. Protein concentration was measured using the Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA). The protein samples were subjected to reducing SDS-PAGE using standard methods, using 40 μg for total-protein and 90 μg for phospho-protein analysis. Western blots were probed with the following antibodies (Cell Signaling) at a dilution 1:1000: phospho-MKK3/6 (#9231), phospho-p38-MAPK (#9211), p38-MAPK (#9212), phospho-p44/42 MAPK-Erk1/2 (#9106), p44/42 MAPK-Erk1/2 (#9102), phopsho-MAPKAPK-2 (#3007) and MAPKAPK-2 (#3042). The expression of α-tubulin (Sigma-Aldrich, T-6074, 1:3000) served as loading control. The human phospho-kinase antibody array (R&D Systems, ARY003, Minneapolis, MN, USA) was used according to the manufacturer's instructions using 300 μg of protein.
Enzyme-linked immunosorbent assay
The cell supernatant was collected and it was quantified for secreted WIF1 with a sandwich enzyme-linked immunosorbent assay (DY134, R&D Systems) following the manufacturer's instructions. Data were normalized to the cell number.
Immunohistochemistry and quantification of migration in vivo
At the time of killing the mouse, brains were extracted, either snap frozen or formalin fixed for 4 h, cut into coronal slices, and paraffin embedded for further analyses. Sections were stained with hematoxylin and eosin, and glial fibrillary acidic protein using standard procedures. For the identification of human (tumor) cells, sections were stained for human nucleolin using the protocol kindly provided by Donna Senger. Slides were treated in citrate buffer pH 6 at 95°C for 60 min, followed by 121°C for 8 min (under pressure) to retrieve the antigen. Sections were treated sequentially with 
RNA isolation and reverse transcription PCR
Total RNA was extracted using the RNeasy total RNA extraction kit (Qiagen, Venlo, Netherlands), and cDNA was synthesized using PrimeScript RT-PCR kit (TAKARA, Otsu, Shiga, Japan). Real-time quantitative PCR was performed with Fast Sybr Green Master Mix (Applied Biosystems, Waltham, MA, USA) using the Rotor-Gene 6000 Real-Time PCR system (Qiagen). The quality of the products was controlled by the melting curve. Transcript levels were normalized against human GAPDH.
53 Already published primers were used for the following genes: WIF1, 10 AXIN2 54 , WNT5A 55 and IL6. 56 Primers were designed using Primer3 57 (Supplementary Table 2 ).
WIF1-induced LN-229 gene expression profile
The LN-229_indWIF1 was seeded (3 × 10 5 cells per small flask, area 2500 mm 2 ) and let adhere for 24 h, and then half of the flasks were induced with DOX. Cells were harvested 48 h after induction, and RNA was extracted. The samples' expression profiles were generated on the Affymetrix GeneChip HG-U133 Plus 2.0 microarray platform (Affymetrix) at the Genomics Platform at the University of Geneva. The analyses were carried out in R (http://www.R-project.org/), using Bioconductor packages. 58 Raw CEL files were processed using the robust multichip average algorithm available in the Affy package (Affymetrix). 59 Probes were filtered using the coefficient of variation. The gene expression profiles are deposited at (GEO Acc# GSE58525).
Statistical analysis
The Student's t-test was used to compare continuous variables between two groups. Survival is visualized by Kaplan-Meier curve and analyzed ] as well as decreased expression of MALAT1. MALAT1 is a long non-coding RNA involved in migration and its downregulation in GBM attenuates migration.
using the log-rank test. P-values o0.05 were considered statistically significant. Results are marked with one asterisk (*) if Po0.05 and two (**) if Po0.01 and with three (***) if Po 0.001. All statistical tests were two sided. Data are presented as mean values with s.d.
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